ALIM רווח נקי למניה (EPS TTM) Alimera Sciences

Insurance payout limits are constraining the pricing power of Alimera Sciences (ALIM), yet the 12-month net income per share trend demonstrates business adaptability, with the metric currently standing at -0.31. Stability is underpinned by a European CMO partner and US-based warehouses. Sales growth for Yutiq and Iluvien, coupled with the prospect of an acquisition by a tech giant, offset the risks and confirm the company's fundamental strength.

Integration costs following the deal with ANI Pharmaceuticals and regulatory pressure on the drug Iluvien are placing significant pressure on the margins of Alimera Sciences (ALIM). The eps_ttm_co metric measures actual earnings per share over the year, excluding the volatility of one-time write-offs. By analyzing the trend of annual net income per share, an investor can see the adjusted efficiency of the business. The current value of -0.31 reflects the actual yield of the asset. The dynamics of this indicator determine the stability of the company's market capitalization.